GAMMA Investing’s Nurix Therapeutics NRIX Stock Holding History

GAMMA Investing’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$30.1K	Buy	1,270 +620	+95%	+$15.5K	﹤0.01%	2690
2026 Q2	$15.8K	Buy	650 +74	+13%	+$1.26K	﹤0.01%	2970
2026 Q1	$8.93K	Buy	576 +75	+15%	+$1.24K	﹤0.01%	3122
2025 Q4	$9.5K	Sell	501 -210	-30%	-$3.02K	﹤0.01%	3002
2025 Q3	$6.57K	Sell	711 -126	-15%	-$1.31K	﹤0.01%	3067
2025 Q2	$9.53K	Sell	837 -343	-29%	-$3.71K	﹤0.01%	2830
2025 Q1	$14K	Sell	1,180 -3,458	-75%	-$57.8K	﹤0.01%	2582
2024 Q4	$87.4K	Sell	4,638 -63	-1%	-$1.44K	0.01%	1208
2024 Q3	$106K	Buy	4,701 +135	+3%	+$3.06K	0.01%	966
2024 Q2	$95.3K	Buy	4,566 +3,424	+300%	+$53.3K	0.01%	805
2024 Q1	$16.8K	Buy	1,142 +703	+160%	+$7.56K	﹤0.01%	1765
2023 Q4	$3.47K	Buy	+439	New	+$3.01K	﹤0.01%	2387

Other funds holding NRIX

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

GAMMA Investing's NRIX Position: Q3 2026 in Review

GAMMA Investing increased its Nurix Therapeutics (NRIX) stake by 95% in Q3 2026, buying an estimated $15.5K and bringing the position to 1,270 shares worth $30.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2690.

GAMMA Investing first reported a position in NRIX in Q4 2023 and has held it in 12 quarters since. The position peaked at $106K in Q3 2024. 4 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

GAMMA Investing held 1,270 shares of Nurix Therapeutics worth $30.1K as of Q3 2026.
GAMMA Investing bought 620 Nurix Therapeutics shares in Q3 2026, an estimated $15.5K.
Nurix Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2690 holding.
GAMMA Investing first reported a position in Nurix Therapeutics in Q4 2023 and has held it in 12 quarters since.
GAMMA Investing's Nurix Therapeutics position peaked at $106K in Q3 2024.
4 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.